CareLit Fachartikel

Efficacy and Safety of Nintedanib in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease: Subgroup Analysis of the SENSCIS Trial by Corticosteroid Use*

R Wiewrodt, M Vonk, O Distler, D Furst, E Hachulla, S Johnson, S Assassi, L Meng, M Quaresma, M Alves, E Clerisme-Beaty, WA Wuyts · Pneumologie · 2020 · Heft S 01 S 01

Dokument
1214457
CareLit-ID
Jahr
2020
Publikation
PDF
nein
Metadaten
DOI
ja
zitierfähig

Bibliografische Angaben

Zeitschrift
Pneumologie
Autor:innen
R Wiewrodt, M Vonk, O Distler, D Furst, E Hachulla, S Johnson, S Assassi, L Meng, M Quaresma, M Alves, E Clerisme-Beaty, WA Wuyts
Ausgabe
Heft S 01 S 01 / 2020
Jahrgang 74
Seiten
–
Erschienen: 2020-03-01 00:00:00
ISSN
0934-8387
DOI
10.1055/s-0039-3403188

Zusammenfassung

Efficacy and Safety of Nintedanib in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease: Subgroup Analysis of the SENSCIS Trial by Corticosteroid Use*

Schlagworte

Efficacy Safety Nintedanib Patients Systemic Sclerosis-Associated Interstitial Disease Subgroup Analysis Senscis Trial Pneumologie